The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Won Jin | - |
dc.contributor.author | Sung, Jae Sook | - |
dc.contributor.author | Lee, Sung Yong | - |
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Kwon, Nak-Jung | - |
dc.contributor.author | Kim, Hae Mi | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Choi, Jung Yoon | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Kim, Ju Won | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.date.accessioned | 2021-08-30T18:09:26Z | - |
dc.date.available | 2021-08-30T18:09:26Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/53906 | - |
dc.description.abstract | Mutations in the EGFR gene downstream signaling pathways may cause receptor-independent pathway activation, making tumors unresponsive to EGFR inhibitors. However, the clinical significance of RAS, PIK3CA or PTEN mutations in NSCLC is unclear. In this study, patients who were initially diagnosed with NSCLC or experienced recurrence after surgical resection were enrolled, and blood samples was collected. Ultra-deep sequencing analysis of cfDNA using Ion AmpliSeq Cancer Hotspot Panel v2 with Proton platforms was conducted. RAS/PIK3CA/PTEN mutations were frequently detected in cfDNA in stage IV NSCLC (58.1%), and a high proportion of the patients (47.8%) with mutations had bone metastases at diagnosis. The frequency of RAS/PIK3CA/PTEN mutations in patients with activating EGFR mutation was 61.7%. The median PFS for EGFR-TKIs was 15.1 months in patients without RAS/PIK3CA/PTEN mutations, and 19.9 months in patients with mutations (p= 0.549). For patients with activating EGFR mutations, the overall survival was longer in patients without RAS/PIK3CA/PTEN mutations (53.8 months vs. 27.4 months). For the multivariate analysis, RAS/PIK3CA/PTEN mutations were independent predictors of poor prognosis in patients with activating EGFR mutations. In conclusion, RAS, PIK3CA and PTEN mutations do not hamper EGFR-TKI treatment outcome; however, they predict a poor OS when activating EGFR mutations coexist. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | EGFR MUTATIONS | - |
dc.subject | PANEL | - |
dc.subject | KRAS | - |
dc.title | The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Sung, Jae Sook | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.contributor.affiliatedAuthor | Choi, Yoon Ji | - |
dc.contributor.affiliatedAuthor | Park, Kyong Hwa | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.3390/jcm9082642 | - |
dc.identifier.wosid | 000564654300001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.9, no.8 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 9 | - |
dc.citation.number | 8 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | EGFR MUTATIONS | - |
dc.subject.keywordPlus | PANEL | - |
dc.subject.keywordPlus | KRAS | - |
dc.subject.keywordAuthor | lung cancer | - |
dc.subject.keywordAuthor | cell-free DNA | - |
dc.subject.keywordAuthor | sequencing | - |
dc.subject.keywordAuthor | mutations | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.